Genevieve M. Gabb

Genevieve M. Gabb

Auto-generated profile, based on publicly available information

Genevieve M. Gabb

Department of Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2016 in Medical Journal of Australia
Verified
Journal Article
Closed access
GGGenevieve M Gabb
Genevieve M Gabb
Arduino MangoniArduino Mangoni
Arduino Mangoni
CACraig S Anderson
Craig S Anderson
DCDiane Cowley
Diane Cowley
JDJohn S Dowden
John S Dowden
LALeonard Arnolda
Leonard Arnolda
Updated recommendations from the National Heart Foundation take into account the findings of recent meta-analyses, systematic reviews and randomised controlled trials

13 February 2018 in Diabetes Care
Verified
Journal Article
Open access
PDF file
EMEmily Jane Meyer
Emily Jane Meyer
GGGenevieve Gabb
Genevieve Gabb
DJDavid Jesudason
David Jesudason
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been linked with diabetic ketoacidosis (DKA) (1-4). However, characteristics of "at-risk" patients are less well described. Clinical cases were collected from South Australia between December 2015 and March 2017.

31 May 2018 in Emergency Medicine Australasia
Verified
Journal Article
Closed access
PDF file
ELEmily Lawton
Emily Lawton
HPHelen Pearce
Helen Pearce
GGGenevieve M Gabb
Genevieve M Gabb

20 February 2017 in Medical Journal of Australia
Verified
Journal Article
Closed access
GGGenevieve M Gabb
Genevieve M Gabb
Arduino MangoniArduino Mangoni
Arduino Mangoni
LALeonard Arnolda
Leonard Arnolda

1 September 2018 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
GCGillian Caughey
Gillian Caughey
GGGenevieve M. Gabb
Genevieve M. Gabb
SRSaffron Ronson
Saffron Ronson
MWMichael Ward
Michael Ward
TBTimothy Beukelman
Timothy Beukelman
VLVidya Limaye
Vidya Limaye
Statin medications inhibit the enzyme hydroxymethylglutaryl–coenzyme A (HMG-CoA) reductase to lower low-density lipoprotein cholesterol to reduce both primary and secondary cardiovascular risk.1 More than 200 million people worldwide are estimated to use statin therapy, which is generally well tolerated by most patients.2 There are potential harms associated with statins, including well-known musculoskeletal adverse effects that include myalgia (estimated prevalence, 7%-29% of all statin users) and the rare, yet severe condition of rhabdomyolysis (incidence, 0.4 per 10 000 person-years).2-4 In most instances these adverse effects resolve when statin treatment is discontinued. However, in the past 2 decades, numerous case reports have suggested that statins might also be associated with the development of inflammatory myositis.5 A recent systematic review identified 16 publications reporting a total of 100 patients with statin-associated autoimmune myopathy.6 These case reports have been further supported by a small case-control study from France7 of 37 patients that reported a significant association between statin exposure and chronic muscle disease, including inflammatory myositis (odds ratio [OR], 2.73; 95% CI, 1.21-6.14), by comparison with population-based matched controls.7

17 June 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
ASAndrew A. Somogyi
Andrew A. Somogyi
DBDaniel T. Barratt
Daniel T. Barratt
EPElizabeth J. Phillips
Elizabeth J. Phillips
KMKylies Moore
Kylies Moore
FIFahmida Ilyas
Fahmida Ilyas
GGGenevieve M. Gabb
Genevieve M. Gabb
Phenytoin drug reaction with eosinophilia and systemic symptoms (DRESS) in 3 Aboriginal Australians positive for HLA‐B*56:02 has been previously reported. We report the allele frequency of HLA‐B*56:02 in 2 South Australian populations, 1 Aboriginal (4.8%, 95% confidence interval 2.4–7.8%) and the other European (0%). We compared the frequency with publicly available information on HLA‐B*56:02 status in other Indigenous Australian (n = 4) and European Australian cohorts (n = 1). In the Indigenous Australian cohorts, HLA‐B*56:02 allele frequency ranged from 1.3 to 19%. We also describe an additional case of phenytoin DRESS (RegiSCAR DRESS score 7) in an Aboriginal Australian that was associated with HLA‐B*56:02 and with CYP2C9*1/*3 genotype. In Aboriginal Australians, phenytoin DRESS appears distinctly linked to HLA‐B*56:02 with an allele carriage rate substantially higher than in Europeans, but also with considerable regional variation. Investigations of human leucocyte antigen and other contributing genes and severe adverse drug reactions in understudied non‐European populations are required to optimize safe medication use and inform risk mitigation strategies.